Oral-Challenge Study: Steady-State High-ORP Water/Gel Relieves AITC- and Capsaicin-Induced Oral Pain in Healthy Volunteers

November 12, 2026 updated by: Dove Medical Press Ltd

Evaluation of Steady-State High-Oxidation-Reduction-Potential Water and Gel for Relief of Oral Pain, Burning and Choking Sensation Provoked by AITC (Wasabi/Horseradish) and Capsaicin (Chili) Among Healthy Human Volunteers

To evaluate the efficacy and safety of stabilized 780±21 mV high-oxidation-potential water to rapidly relieve oral mucosal pain and irritation induced by AITC (wasabi-horseradish) and capsaicin (chili-oil), which activate TRPA1 and TRPV1 sensory ion-channels. Healthy volunteers receive oral 40 mL stabilized high-oxidation-potential water after oral irritant challenge. Pain-irritation NRS scores are assessed at baseline, 3 seconds, 30 seconds, 60 seconds, 120 seconds post-treatment. Safety observations are recorded throughout the study.

Study Overview

Detailed Description

This is prospective, single-arm, open-label exploratory pilot study in healthy adult volunteers. Two separate oral irritant challenge models are applied: AITC-containing horseradish-wasabi challenge for TRPA1-mediated oral irritation-pain; capsaicin-containing chili-oil challenge for TRPV1-mediated burning oral pain. Total target enrollment is 24 healthy subjects (12 male,12 female). After irritant exposure, subjects take 40 mL stabilized 780±21 mV high-oxidation-potential water, hold in mouth then swallow. Subject-reported 0-10 NRS pain-irritation scores are collected at pre-challenge baseline; post-irritant baseline; 3 s,30 s,60 s,120 s after study product administration. Local oral-mucosal adverse reactions and systemic tolerability are monitored. Pre-existing rabbit ocular-surface safety testing supports mucosal safety of this formulation. This trial focuses on acute seconds-range symptom relief in experimental irritant-pain models.

Study Type

Interventional

Enrollment (Estimated)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Shandong
      • Qingdao, Shandong, China, 266000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Healthy adult volunteers aged 18-60 years old, male and female.
  2. Body weight range 40 kg-72 kg.
  3. No active oral-pharyngeal disease, no oral ulcer, gingivitis, pharyngitis at screening.
  4. Able to understand trial procedure, independently complete NRS numeric rating scale assessments.
  5. Voluntarily provide written informed consent.

Exclusion Criteria:

  1. Active oral ulcer, stomatitis, gingival-periodontal acute disease, active pharyngitis.
  2. Known hypersensitivity to electrolyzed saline / study formulation components.
  3. Gastro-esophageal reflux disease, active gastrointestinal disorder.
  4. Pregnant or lactating women.
  5. Recent consumption (<72 hours) of large-dose spicy / irritant food interfering with pain perception.
  6. Concurrent participation in other oral-pain or mucosal-related clinical research.
  7. Psychiatric condition impairing study compliance.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Stabilized High-Oxidation-Potential Oral Water

Intervention description: Stabilized electrolyzed saline water with oxidation-potential 780±21 mV. After oral irritant challenge (AITC-horseradish-wasabi or capsaicin-chili-oil), subject takes 40 mL of study liquid, holds in oral cavity briefly then swallow, single administration for each challenge test.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
AITC-Induced Oral Pain-Irritation NRS Score
Time Frame: Post-irritant baseline, 3 seconds, 30 seconds post-product administration.

Participant self-reported 0-10 numerical rating scale for oral pain, stinging, choking-irritation triggered by AITC-containing horseradish-wasabi; 0 = no pain/irritation, 10 = worst imaginable oral irritation-pain.

Post-irritant baseline, 3 seconds, 30 seconds post-product administration.
Capsaicin-Induced Oral Burning-Pain NRS Score
Time Frame: Post-irritant baseline, 3 seconds, 30 seconds, 60 seconds,120 seconds post-product administration.

Participant self-reported 0-10 NRS for burning-pain triggered by capsaicin-containing chili-oil; 0 = no burning-pain,10 = worst imaginable burning-pain.

Post-irritant baseline, 3 seconds, 30 seconds, 60 seconds,120 seconds post-product administration.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participant Overall Subjective Relief Assessment Score
Time Frame: 120 seconds after product administration for each irritant challenge.

Subject-rated 0-10 scale for overall subjective relief of oral discomfort after each challenge test;0=no relief,10=complete relief.

120 seconds after product administration for each irritant challenge.
Incidence of Adverse Events
Time Frame: Throughout entire study visit period (within 30 minutes of product exposure).

Incidence of product-related adverse events including oral mucosal stinging, numbness, gastrointestinal upset, throat irritation, nausea.

Throughout entire study visit period (within 30 minutes of product exposure).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 15, 2026

Primary Completion (Estimated)

December 22, 2026

Study Completion (Estimated)

January 10, 2027

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe